2026-10-12T06:27:02Z https://data.mendeley.com/oai

oai:data.mendeley.com/fjvbg94t78.1 2023-08-29T12:51:33Z

Zhou, Kunli An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab. Mendeley Supplements. Mendeley Data 1. Supplemental Materials including: Supplementary Figure 1: Flow diagram of study; Supplementary Figure 2: Numbers of AD patients achieving EASI 25/50/75 at week 2, 4, 8 and week 12. Supplementary Figure 3: Numbers of AD patients achieving SCORAD 25/50/75 at week 2, 4, 8 and week 12. Supplementary Figure 4: Clinical photographs and the EASI score of two typical patients during the follow-up. Supplemental Table 1: Demographic and clinical characteristics of 16 patients. Supplemental Table 2: Laboratory parameters before and during abrocitinib treatment. 2.Supplemental Methods Biologicals Switch Atopic Dermatitis Janus Kinase Dataset doi:10.17632/fjvbg94t78.1 oai:data.mendeley.com/fjvbg94t78.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/fjvbg94t78 2023-08-29T12:51:33Z